Literature DB >> 17027068

Summary and discussion of session recommendations.

Jane Fountain1, Edward Trimble, Michael J Birrer.   

Abstract

Mesh：

Year:  2006        PMID： 17027068     DOI： 10.1016/j.ygyno.2006.08.022

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


× No keyword cloud information.
  7 in total

1.  The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma.

Authors:  Jane A Cipollone; Marcia L Graves; Martin Köbel; Steve E Kalloger; Tak Poon; C Blake Gilks; Kelly M McNagny; Calvin D Roskelley
Journal:  Clin Exp Metastasis       Date:  2012-01-20       Impact factor: 5.150

Review 2.  Proteomics of ovarian cancer: functional insights and clinical applications.

Authors:  Mohamed A Elzek; Karin D Rodland
Journal:  Cancer Metastasis Rev       Date:  2015-03       Impact factor: 9.264

3.  Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers.

Authors:  K D Swenerton; J L Santos; C B Gilks; M Köbel; P J Hoskins; F Wong; N D Le
Journal:  Ann Oncol       Date:  2010-08-06       Impact factor: 32.976

Review 4.  Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features.

Authors:  Jaime Prat
Journal:  Virchows Arch       Date:  2012-02-10       Impact factor: 4.064

5.  Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis.

Authors:  Shuai Zhen; Li-Hong Bian; Li-Li Chang; Xin Gao
Journal:  Mol Clin Oncol       Date:  2014-04-16

6.  Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.

Authors:  Martin Köbel; Steve E Kalloger; Niki Boyd; Steven McKinney; Erika Mehl; Chana Palmer; Samuel Leung; Nathan J Bowen; Diana N Ionescu; Ashish Rajput; Leah M Prentice; Dianne Miller; Jennifer Santos; Kenneth Swenerton; C Blake Gilks; David Huntsman
Journal:  PLoS Med       Date:  2008-12-02       Impact factor: 11.069

7.  HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy.

Authors:  Jessica N McAlpine; Kimberly C Wiegand; Russell Vang; Bridgett M Ronnett; Anna Adamiak; Martin Köbel; Steve E Kalloger; Kenneth D Swenerton; David G Huntsman; C Blake Gilks; Dianne M Miller
Journal:  BMC Cancer       Date:  2009-12-10       Impact factor: 4.430
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.